The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Natco Pharma intends to defend the matter accordingly
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Acquisition of exclusive commercialization rights for European markets
Subscribe To Our Newsletter & Stay Updated
